107 related articles for article (PubMed ID: 16320944)
1. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility.
Gupta P; Bansal AK
Pharmazie; 2005 Nov; 60(11):830-6. PubMed ID: 16320944
[TBL] [Abstract][Full Text] [Related]
2. Molecular interactions in celecoxib-PVP-meglumine amorphous system.
Gupta P; Bansal AK
J Pharm Pharmacol; 2005 Mar; 57(3):303-10. PubMed ID: 15807985
[TBL] [Abstract][Full Text] [Related]
3. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems.
Gupta P; Bansal AK
PDA J Pharm Sci Technol; 2005; 59(6):346-54. PubMed ID: 16471422
[TBL] [Abstract][Full Text] [Related]
4. Role of molecular interaction in stability of celecoxib-PVP amorphous systems.
Gupta P; Thilagavathi R; Chakraborti AK; Bansal AK
Mol Pharm; 2005; 2(5):384-91. PubMed ID: 16196491
[TBL] [Abstract][Full Text] [Related]
5. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.
Gupta P; Kakumanu VK; Bansal AK
Pharm Res; 2004 Oct; 21(10):1762-9. PubMed ID: 15553220
[TBL] [Abstract][Full Text] [Related]
6. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
7. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine.
Gupta P; Bansal AK
Pharm Dev Technol; 2005; 10(2):273-81. PubMed ID: 15926676
[TBL] [Abstract][Full Text] [Related]
8. Devitrification of amorphous celecoxib.
Gupta P; Bansal AK
AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study.
Grzybowska K; Paluch M; Wlodarczyk P; Grzybowski A; Kaminski K; Hawelek L; Zakowiecki D; Kasprzycka A; Jankowska-Sumara I
Mol Pharm; 2012 Apr; 9(4):894-904. PubMed ID: 22384922
[TBL] [Abstract][Full Text] [Related]
10. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
Ambrogi V; Perioli L; Marmottini F; Rossi C
Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
[TBL] [Abstract][Full Text] [Related]
11. Co-relationship of physical stability of amorphous dispersions with enthalpy relaxation.
Bansal SS; Kaushal AM; Bansal AK
Pharmazie; 2008 Nov; 63(11):812-4. PubMed ID: 19069241
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential.
Remenar JF; Peterson ML; Stephens PW; Zhang Z; Zimenkov Y; Hickey MB
Mol Pharm; 2007; 4(3):386-400. PubMed ID: 17497886
[TBL] [Abstract][Full Text] [Related]
13. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64.
Weuts I; Kempen D; Decorte A; Verreck G; Peeters J; Brewster M; Van den Mooter G
Eur J Pharm Sci; 2005 Jun; 25(2-3):313-20. PubMed ID: 15911228
[TBL] [Abstract][Full Text] [Related]
14. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
[TBL] [Abstract][Full Text] [Related]
15. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
Gupta P; Chawla G; Bansal AK
Mol Pharm; 2004; 1(6):406-13. PubMed ID: 16028352
[TBL] [Abstract][Full Text] [Related]
16. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2011 Jun; 100(6):2460-8. PubMed ID: 21246560
[TBL] [Abstract][Full Text] [Related]
17. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights.
Grzybowska K; Chmiel K; Knapik-Kowalczuk J; Grzybowski A; Jurkiewicz K; Paluch M
Mol Pharm; 2017 Apr; 14(4):1154-1168. PubMed ID: 28241116
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques.
van Drooge DJ; Hinrichs WL; Visser MR; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):220-9. PubMed ID: 16427226
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
[TBL] [Abstract][Full Text] [Related]
20. Impact of surfactants on the crystal growth of amorphous celecoxib.
Mosquera-Giraldo LI; Trasi NS; Taylor LS
Int J Pharm; 2014 Jan; 461(1-2):251-7. PubMed ID: 24333451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
